SLAMF6 蛋白, Human (HEK293, His-Avi)

SLAMF6 Protein, a self-ligand receptor in the SLAM family, crucially modulates immune cell activation and differentiation, orchestrating innate and adaptive immune responses. Regulated by cytoplasmic adapters like SH2D1A/SAP and/or SH2D1B/EAT-2, SLAMF6 triggers NK cell cytolytic activity, involving VAV1 phosphorylation and SH2D1B dependence. Teaming with SLAMF1, it guides thymocytic NKT cell lineage transition. SLAMF6 promotes Th17 differentiation, potentially negatively regulates humoral immune response, and, in the absence of SH2D1A/SAP, transmits negative signals to CD4(+) T-cells and NKT cells, inhibiting germinal center formation and contributing to B-cell tolerance. SLAMF6, existing as a homodimer, interacts with PTN6, PTN11, SH2D1A/SAP, and SH2D1B/EAT2. Both adapter proteins can associate with the same SLAMF6 molecule, mediated by ITSM 2. SLAMF6 Protein, Human (HEK293, His-Avi) is the recombinant human-derived SLAMF6 protein, expressed by HEK293, with C-Avi, C-6*His labeled tag. The total length of SLAMF6 Protein, Human (HEK293, His-Avi) is 204 a.a., with molecular weight of 35-50 kDa.

SLAMF6 是信号淋巴细胞激活分子 (SLAM) 家族中的一种自配体受体，在调节多种免疫细胞的激活和分化中发挥着至关重要的作用，有助于先天性和适应性免疫反应的复杂调节和协调。SLAMF6 的活性通过小细胞质接头蛋白（例如 SH2D1A/SAP 和/或 SH2D1B/EAT-2）的存在或不存在来精细控制。值得注意的是，SLAMF6 特别在表达高表面密度天然细胞毒性受体的自然杀伤 (NK) 细胞中触发细胞溶解活性，并在 NK 细胞中参与正信号传导，涉及 VAV1 的磷酸化和对 SH2D1B 而不是 SH2D1A 的依赖。SLAMF6 与 SLAMF1 一起控制胸腺细胞自然杀伤 T (NKT) 细胞谱系的转变和分化。此外，SLAMF6 促进 T 细胞分化为 Th17 表型，导致 IL-17 分泌增加，并与 SLAMF1 和 CD84/SLAMF5 协同作用，作为体液免疫反应的潜在负调节因子。此外，在缺乏SH2D1A/SAP的情况下，SLAMF6可以向CD4(+) T细胞和NKT细胞传递负信号，负向调节生发中心的形成，并可能有助于生发中心的B细胞耐受，同时防止自身免疫。SLAMF6 以同二聚体形式存在，并与 PTN6 和 PTN11 以及 SH2D1A/SAP 和 SH2D1B/EAT2 相互作用，两种接头蛋白都能够在 ITSM 2 介导下与相同的 SLAMF6 分子结合。

Human

HEK293

C-Avi;C-6*His

Q96DU3-1 (Q22-K225)

114836  [NCBI]

QSSLTPLMVNGILGESVTLPLEFPAGEKVNFITWLFNETSLAFIVPHETKSPEIHVTNPKQGKRLNFTQSYSLQLSNLKMEDTGSYRAQISTKTSAKLSSYTLRILRQLRNIQVTNHSQLFQNMTCELHLTCSVEDADDNVSFRWEALGNTLSSQPNLTVSWDPRISSEQDYTCIAENAVSNLSFSVSAQKLCEDVKIQYTDTK

35-50 kDa

Greater than 95% as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.